Recent Quotes (30 days)

You have no recent quotes
chg | %

Ceapro Inc.  

(Public, CVE:CZO)   Watch this stock  
Find more results for CZO
+0.010 (1.39%)
May 3 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.71 - 0.75
52 week 0.17 - 0.80
Open 0.73
Vol / Avg. 86,700.00/80,094.00
Mkt cap 46.37M
P/E 8.83
Div/yield     -
EPS 0.08
Shares 62.64M
Beta 1.94
Inst. own     -
May 30, 2016
Q1 2016 Ceapro Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Apr 14, 2016
Q4 2015 Ceapro Inc Earnings Release

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 100.51% 46.14%
Operating margin 53.72% 34.03%
EBITD margin - 39.32%
Return on average assets 103.99% 42.09%
Return on average equity 228.99% 98.75%
Employees 12 -
CDP Score - -


7824 51 Avenue
+1-780-4214555 (Phone)
+1-780-4211320 (Fax)

Website links


Ceapro Inc. is a Canada-based growth-stage biotechnology company. The Company's primary business activities relate to the marketing and development of health and wellness products and technology relating to plant extracts. It develops and commercializes natural products for personal care, cosmetic, human and animal health industries. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides and lupin peptides, and Veterinary therapeutic products, including an oat shampoo, an ear cleanser and a dermal complex/conditioner, which are manufactured and marketed to veterinarians in Japan and Asia. Its wholly owned subsidiaries include Ceapro Technology Inc., Ceapro Veterinary Products Inc., Ceapro Active Ingredients Inc., Ceapro BioEnergy Inc., Ceapro (P.E.I.) Inc. and Ceapro USA Inc.

Officers and directors

Gilles R. Gagnon Chief Executive Officer, Director
Age: 61
Stacy Prefontaine Chief Financial Officer, Corporate Secretary
Glenn R. Rourke Independent Chairman of the Board
Ulrich Kosciessa Director
William W. Li M.D. Director
Age: 50
Donald J. Oborowsky Independent Director
John Zupancic Independent Director